Cyclosporine News and Research

RSS

Cyclosporine is a drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.

3 May 2010

No single immunosuppressive medication increases cancer risk in kidney transplant recipients

Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that no single medication is to blame for the higher incidence of cancer seen among patients who have undergone transplantation.

30 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

IP Advocate founder settles long-standing legal battle with UGARF

In a move that positions IP Advocate for its next chapter as a champion of research translation, founder Dr. Renee Kaswan today announced that she has settled her long-standing legal battle with the University of Georgia Research Foundation.

21 Apr 2010

Japanese ministry approves DIQUAS Ophthalmic Solution 3% for dry eye treatment

Santen Pharmaceutical Co., Ltd. and Inspire Pharmaceuticals, Inc. announced today that the Japanese Ministry of Health, Labour and Welfare granted approval for the new dry eye treatment drug, DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium), on April 16, 2010.

From Santen Pharmaceutical Co., Ltd. 17 Apr 2010

Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment

Drug discovery company SCYNEXIS, Inc. today presented data supporting an impressive resistance profile for SCY-635—a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection. In the study, SCYNEXIS demonstrated that the hepatitis C virus required multiple mutations across two separate proteins in order to establish resistance to SCY-635. The majority of HCV drugs on the market and in development require only one targeted viral mutation to establish resistance.

16 Apr 2010

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company's cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria, April 14-18, 2010.

6 Apr 2010

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company's lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at 11:15 am ET at the Peninsula Hotel in New York City.

31 Mar 2010

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Alcon, the world's leader in eye care, announced today that it received regulatory approval and finalized the acquisition of the rights in the United States for DUREZOL™ emulsion and the global rights, excluding Latin America, for ZYCLORIN™ from Sirion Therapeutics, Inc.

30 Mar 2010

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Isotechnika Pharma Inc. has released its financial results for the fourth quarter and year ended December 31, 2009 and provided a review of the Company's operational and scientific highlights for 2009

25 Mar 2010

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Inspire Pharmaceuticals, Inc. announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue pursuing a potential indication for treatment of anterior and posterior forms of blepharitis.

15 Mar 2010

Isotechnika Pharma receives grant of $237,069 to support NICAM program

Isotechnika Pharma Inc. today announced that it has received funding approval from the National Research Council's Industrial Research Assistance Program (IRAP) for its Non-Immunosuppressive Cyclosporin Analog Molecules (NICAM) program.

5 Mar 2010

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.

4 Mar 2010

Belatacept drug can prevent graft rejection in kidney transplant recipients

The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.

4 Mar 2010

Belatacept costimulation blocker can prevent rejection of new organs by the immune system

Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class costimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide similar patient and graft survival to cyclosporine but with fewer side effects and superior kidney function after 12 months. The study, published today in the American Journal of Transplantation, provides the first findings to come from BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial).

17 Feb 2010

USPTO issues two new patents for EKR Therapeutics' RTU Cardene I.V. Premixed Injection

EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing acute-care hospital products, today announced that the US Patent and Trademark Office has issued two new patents covering methods of treatment and methods of preparation for the Company’s Ready-to-Use (RTU) Cardene® I.V. (nicardipine hydrochloride) Premixed Injection.

17 Feb 2010

Ulcerative colitis drug market to grow up to $2.1 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ulcerative colitis drug market will nearly double from $1.2 billion in 2008 to $2.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

12 Feb 2010

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.

11 Feb 2010

Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.

9 Feb 2010

Phase 3 clinical trial results of Inspire Pharmaceuticals' PROLACRIA announced

Inspire Pharmaceuticals, Inc. announced today that its Phase 3 clinical trial (Trial 03-113) of PROLACRIA™ (diquafosol tetrasodium ophthalmic solution) 2% for the treatment of dry eye disease did not meet its primary endpoint (p = 0.526) or its secondary endpoint (p = 0.368).

21 Jan 2010